bluebird bio, Inc.
(NASDAQ : BLUE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -0.35%62.981.0%$472.19m
AMGNAmgen, Inc. 0.41%241.491.3%$448.51m
BIIBBiogen, Inc. -0.22%285.501.4%$387.69m
ILMNIllumina, Inc. -0.38%324.723.5%$323.34m
VRTXVertex Pharmaceuticals, Inc. 0.14%235.831.9%$300.14m
REGNRegeneron Pharmaceuticals, Inc. 0.10%385.942.6%$230.50m
EXASEXACT Sciences Corp. -1.92%88.0624.0%$205.44m
ALXNAlexion Pharmaceuticals, Inc. 0.68%113.272.0%$195.57m
ITCIIntra-Cellular Therapies, Inc. -1.43%26.259.0%$173.00m
INCYIncyte Corp. -0.15%80.502.5%$148.96m
SRPTSarepta Therapeutics, Inc. -1.84%127.9014.6%$138.72m
ARWRArrowhead Pharmaceuticals, Inc. -1.21%56.4211.3%$132.45m
SGENSeattle Genetics, Inc. 1.25%109.006.1%$122.98m
AAgilent Technologies, Inc. 0.79%90.171.6%$113.52m
BMRNBioMarin Pharmaceutical, Inc. -0.97%88.274.3%$108.30m

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.